Breaking barriers in healthcare affordability, California is set to revolutionize insulin access with its groundbreaking CalRx® program. Starting January 1, 2026, Californians will be able to purchase insulin pens at just $11 each, a game-changing initiative that puts people’s health over pharmaceutical profits.

Governor Gavin Newsom has been leading the charge in making essential medications accessible, and this latest move demonstrates California’s commitment to addressing the insulin affordability crisis. By partnering with Civica Rx, a nonprofit generic drug manufacturer, the state is becoming the first in the nation to contract its own affordable insulin.

The CalRx® insulin glargine pens will be interchangeable with Lantus®, ensuring patients can seamlessly switch without disrupting their treatment. This approach not only provides financial relief but also challenges the existing pharmaceutical market’s pricing model.

Ned McCoy, President and CEO of Civica, emphasized the shared vision of creating a sustainable and quality supply of essential medicines. The initiative is particularly crucial as healthcare costs continue to burden many Americans, especially those managing chronic conditions like diabetes.

California’s strategy extends beyond insulin. Recent legislation like SB 40 and SB 41 aims to cap consumer cost-sharing and regulate pharmacy benefit managers, further demonstrating the state’s comprehensive approach to healthcare affordability.

This bold step is part of Governor Newsom’s broader mission, initiated in 2019, to lower prescription drug costs and ensure transparent, fair pricing. By taking direct action, California is setting a precedent for other states to follow, showing that innovative policy can challenge systemic healthcare inequities.

For those struggling with diabetes, this announcement offers hope. No longer will patients have to choose between their health and financial stability. The CalRx® program represents more than just affordable medication – it’s a statement that healthcare is a fundamental right, not a luxury.